Genzyme Seeks Approval for Leukemia Medication
Recent reports claimed that Genzyme Corp. recently filed a new drug request with the U.S. Food and Drug Administration for a potential leukemia treatment. The company has been doing ongoing research on clofarabine and has supposedly found that the drug could help treat adult patients living with acute myeloid leukemia.
Genzyme has reportedly requested that the FDA conduct a priority review of the medication so it can begin being used to treat patients in the first half of the new year.
Drug Approved for Acute Lymphoblastic Leukemia
Clofarabine has already been approved to treat acute lymphoblastic leukemia and has proven to be beneficial in patients. The drug has been used to treat relapsed and refractory pediatric patients who are between the ages of one and 21 years old. Now, the Genzyme is hoping the FDA will see how beneficial the medication can also be for patients living with acute myeloid leukemia.
Details of Leukemia Medication
Clorfarabine has been sold under the brand name Clolar in the U.S. market and was developed by ILEX Oncology, which is based out of San Antonio, Texas. ILEX is reportedly a predecessor company to Genzyme Oncology, which is headquartered in Cambridge, Massachusetts. The drug was originally created to target certain drugs, aside from leukemia; however, researchers are finding that it could be the effective treatment needed to help patients living with this sometimes fatal illness.
Genzyme and its partner company, along with researchers who have worked hard to uncover the benefits of this medication are hoping that the FDA will work fast for patients to begin being treated.
